We are a clinical-stage biopha
Pioneering a novel class of therapeutics in Oncology and Immuno-Dysregulated Diseases
We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx), which we believe will replace first-line therapies across a multitude of cancer indications.
ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma News provided byImmix Biopharma, Inc.Sep 30, 2021, 08:38 ET LOS ANGELES, Sept. 30, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and […]
ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors Novel Approach Combining ImmixBio Tissue Specific Therapeutics (TSTx)™ with Immunotherapies Could Expand the Population Of Cancer Patients Experiencing Extended Remissions News provided byImmix Biopharma, Inc.Aug 27, 2021, […]
ImmixBio Announces Dr. Galit Lahav of Harvard Medical School Joins Scientific Advisory Board Dr. Galit Lahav, pioneer of understanding why individual human cancer cells often show different responses to the same treatment (including p53 and NF-kB signaling dynamics), and identifying new therapies that will increase the […]
More Events are coming soon.
More information is coming soon.